Andrew H. Galligan - 28 Apr 2026 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Reporting relationship: Director
Issuer ticker: ACLX
Reported as of: 28 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Apr 2026, 16:26:51 UTC
Prior SEC filing: 24 Jun 2025
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michelle Gilson, as Attorney-in-Fact

Key filing fact

Andrew H. Galligan filed Form 4 for Arcellx, Inc. (ACLX) on 28 Apr 2026.

Key facts

This page summarizes Andrew H. Galligan's Form 4 filing for Arcellx, Inc. (ACLX).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Apr 2026, 16:26.

Change

Previous filing in this sequence was filed on 24 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001417976 Primary reporting owner

Galligan Andrew H

Relationship: Director
Address: C/O ARCELLX, INC., 800 BRIDGE PARKWAY, REDWOOD CITY
Signature: /s/ Michelle Gilson, as Attorney-in-Fact
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACLX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -5,000
Change %: -100%
Price
Shares after: 0
Date: 28 Apr 2026
Ownership: By trust
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACLX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -16,829
Change %: -100%
Price
Shares after: 0
Date: 28 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,829
Exercise price: $69.87
Footnotes: F2

ACLX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,784
Change %: -100%
Price
Shares after: 0
Date: 28 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,784
Exercise price: $63.68
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Andrew H. Galligan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

Footnote F2

Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.